These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14748435)

  • 1. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: cytolytic activity of spleen cells from tumour regressors.
    Indrová M; Mikysková R; Jandlová T; Vonka V; Bubeník J; Bieblová J
    Folia Biol (Praha); 2003; 49(6):217-22. PubMed ID: 14748435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
    Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
    Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin 2 gene therapy of surgical minimal residual tumour disease: characterization of cytolytic effector cells from tumour progressors and regressors.
    Hájková R; Indrová M; Jandlová T; Bubeník J; Reinis M
    Folia Biol (Praha); 1999; 45(6):227-31. PubMed ID: 10732718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
    Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
    Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
    Indrová M; Bubeník J; Mikysková R; Vonka V; Smahel M; Zák R; Símová J; Bieblová J; Mendoza L; Jandlová T
    Int J Oncol; 2002 Mar; 20(3):643-6. PubMed ID: 11836582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
    Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
    Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local IFN-gamma therapy of HPV16-associated tumours.
    Mikysková R; Bieblová J; Símová J; Indrová M; Jandlová T; Vonka V; Smahel M; Bubeník J; Mendoza L
    Folia Biol (Praha); 2003; 49(1):26-32. PubMed ID: 12630665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
    Reinis M; Indrová M; Mendoza L; Mikysková R; Bieblová J; Bubeník J; Símová J
    Int J Oncol; 2004 Oct; 25(4):1165-70. PubMed ID: 15375569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class I+ and class I- HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.
    Símová J; Mikysková R; Vonka V; Bieblová J; Bubeník J; Jandlová T
    Folia Biol (Praha); 2003; 49(6):230-4. PubMed ID: 14748438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours.
    Símová J; Bubeník J; Bieblová J; Rosalia RA; Fric J; Reinis M
    Int J Oncol; 2006 Dec; 29(6):1567-71. PubMed ID: 17088998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissimilar anti-tumour reactions induced by tumour cells engineered with the interleukin-2 or interleukin-15 gene in nude mice.
    Di Carlo E; Meazza R; Basso S; Rosso O; Comes A; Gaggero A; Musiani P; Santi L; Ferrini S
    J Pathol; 2000 Jun; 191(2):193-201. PubMed ID: 10861581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.
    Reinis M; Símová J; Indrová M; Bieblová J; Bubeník J
    Int J Oncol; 2007 May; 30(5):1247-51. PubMed ID: 17390028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.
    Bubeník J; Símová J; Hájková R; Sobota V; Jandlová T; Smahel M; Sobotková E; Vonka V
    Int J Oncol; 1999 Mar; 14(3):593-7. PubMed ID: 10024696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV 16-associated tumours: IL-12 can repair the absence of cytotoxic and proliferative responses of tumour infiltrating cells after chemotherapy.
    Indrová M; Bieblová J; Rossowska J; Kuropka P; Pajtasz-Piasecka E; Bubeník J; Reinis M
    Int J Oncol; 2009 Jan; 34(1):173-9. PubMed ID: 19082488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Live cell vaccines expressing B7.1, monocyte chemoattractant protein 1 and granulocyte-macrophage colony stimulation factor derived from mouse HPV16-transformed cells.
    Lakatosová-Andelová M; Jinoch P; Dusková M; Marinov I; Vonka V
    Int J Oncol; 2008 Jan; 32(1):265-71. PubMed ID: 18097567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules.
    Nemeckova S; Smahel M; Hainz P; Mackova J; Zurkova K; Gabriel P; Indrova M; Kutinova L
    Neoplasma; 2007; 54(4):326-33. PubMed ID: 17822323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells.
    Sobotková E; Dusková M; Smahel M; Holán V; Janousková O; Vonka V
    Oncol Rep; 2004 Oct; 12(4):877-83. PubMed ID: 15375516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model.
    Welters MJ; Filippov DV; van den Eeden SJ; Franken KL; Nouta J; Valentijn AR; van der Marel GA; Overkleeft HS; Lipford G; Offringa R; Melief CJ; van Boom JH; van der Burg SH; Drijfhout JW
    Vaccine; 2004 Dec; 23(3):305-11. PubMed ID: 15530672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.